A citation-based method for searching scientific literature

Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Eric Lespessailles, Stephen Hall, Marla Hochfeld, ChiaChi Hu, Douglas Hough, Randall M Stevens, Georg Schett. Ann Rheum Dis 2014
Times Cited: 284







List of co-cited articles
1032 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
Christopher J Edwards, Francisco J Blanco, Jeffrey Crowley, Charles A Birbara, Janusz Jaworski, Jacob Aelion, Randall M Stevens, Adele Vessey, Xiaojiang Zhan, Paul Bird. Ann Rheum Dis 2016
152
59

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
Maurizio Cutolo, Gary E Myerson, Roy M Fleischmann, Frédéric Lioté, Federico Díaz-González, Filip Van den Bosch, Helena Marzo-Ortega, Eugen Feist, Kamal Shah, ChiaChi Hu,[...]. J Rheumatol 2016
114
54

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
516
45


Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Proton Rahman, Désirée van der Heijde, Robert Landewé, Philip G Conaghan, Alice B Gottlieb,[...]. Lancet 2015
522
40

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
243
38

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
256
37

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
517
35

Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
P J Mease, R Fleischmann, A A Deodhar, J Wollenhaupt, M Khraishi, D Kielar, F Woltering, C Stach, B Hoepken, T Arledge,[...]. Ann Rheum Dis 2014
303
35

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
303
35

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
115
33

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan,[...]. N Engl J Med 2015
482
32

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
Philip J Mease, Dafna D Gladman, Christopher T Ritchlin, Eric M Ruderman, Serge D Steinfeld, Ernest H S Choy, John T Sharp, Peter A Ory, Renee J Perdok, Mark A Weinberg. Arthritis Rheum 2005
676
32

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha,[...]. Ann Rheum Dis 2016
579
32

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
218
31

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
570
31

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
Arthur Kavanaugh, Iain McInnes, Philip Mease, Gerald G Krueger, Dafna Gladman, Juan Gomez-Reino, Kim Papp, Julie Zrubek, Surekha Mudivarthy, Michael Mack,[...]. Arthritis Rheum 2009
443
29

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh. Ann Rheum Dis 2005
517
28

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Philip J Mease, Alan J Kivitz, Francis X Burch, Evan L Siegel, Stanley B Cohen, Peter Ory, David Salonen, Joel Rubenstein, John T Sharp, Wayne Tsuji. Arthritis Rheum 2004
682
28

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E Furst, Jerry Molitor, Edward Keystone, Dafna Gladman,[...]. Arthritis Rheum 2005
481
25

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
P J Mease, B S Goffe, J Metz, A VanderStoep, B Finck, D J Burge. Lancet 2000
24

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
23

Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.
Georg Schett, Jurgen Wollenhaupt, Kim Papp, Rik Joos, Jude F Rodrigues, Adele R Vessey, ChiaChi Hu, Randall Stevens, Kurt L de Vlam. Arthritis Rheum 2012
147
23

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Marla Hochfeld, Lichen L Teng, Georg Schett, Eric Lespessailles,[...]. J Rheumatol 2015
87
24

Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial.
Alvin F Wells, Christopher J Edwards, Alan J Kivitz, Paul Bird, Dianne Nguyen, Maria Paris, Lichen Teng, Jacob A Aelion. Rheumatology (Oxford) 2018
41
51


A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
Gabrielle H Kingsley, Anna Kowalczyk, Helen Taylor, Fowzia Ibrahim, Jonathan C Packham, Neil J McHugh, Diarmuid M Mulherin, George D Kitas, Kuntal Chakravarty, Brian D M Tom,[...]. Rheumatology (Oxford) 2012
219
19

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
Peter Nash, Kamal Ohson, Jessica Walsh, Nikolay Delev, Dianne Nguyen, Lichen Teng, Juan J Gómez-Reino, Jacob A Aelion. Ann Rheum Dis 2018
43
44

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
108
19

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser,[...]. Ann Rheum Dis 2018
143
18


Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.
Philip J Mease, Mark C Genovese, Maria W Greenwald, Christopher T Ritchlin, André D Beaulieu, Atul Deodhar, Richard Newmark, JingYuan Feng, Ngozi Erondu, Ajay Nirula. N Engl J Med 2014
269
17

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
Laura C Coates, Anna R Moverley, Lucy McParland, Sarah Brown, Nuria Navarro-Coy, John L O'Dwyer, David M Meads, Paul Emery, Philip G Conaghan, Philip S Helliwell. Lancet 2015
260
16

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Kim Papp, Kristian Reich, Craig L Leonardi, Leon Kircik, Sergio Chimenti, Richard G B Langley, ChiaChi Hu, Randall M Stevens, Robert M Day, Kenneth B Gordon,[...]. J Am Acad Dermatol 2015
323
16


Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
15

Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
D D Gladman, C Antoni, P Mease, D O Clegg, P Nash. Ann Rheum Dis 2005
896
14


Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Philip Mease, Mark C Genovese, Geoffrey Gladstein, Alan J Kivitz, Christopher Ritchlin, Paul P Tak, Jürgen Wollenhaupt, Orna Bahary, Jean-Claude Becker, Sheila Kelly,[...]. Arthritis Rheum 2011
215
14

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Mark C Genovese, Philip J Mease, Glen T D Thomson, Alan J Kivitz, Renee J Perdok, Mark A Weinberg, John Medich, Eric H Sasso. J Rheumatol 2007
149
14

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Jeffrey Crowley, Diamant Thaçi, Pascal Joly, Ketty Peris, Kim A Papp, Joana Goncalves, Robert M Day, Rongdean Chen, Kamal Shah, Carlos Ferrándiz,[...]. J Am Acad Dermatol 2017
95
13

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Jocelyn H Leu, Elizabeth C Hsia. Arthritis Rheumatol 2017
64
20

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
171
13

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison,[...]. Lancet 2018
98
13

Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study.
Elizabeth G Araujo, Matthias Englbrecht, Sabrina Hoepken, Stephanie Finzel, Eleni Kampylafka, Arnd Kleyer, Sarah Bayat, Verena Schoenau, Axel Hueber, Juergen Rech,[...]. Semin Arthritis Rheum 2019
60
21

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
91
14

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
Zoe Ash, Cécile Gaujoux-Viala, Laure Gossec, Elizabeth M A Hensor, Oliver FitzGerald, Kevin Winthrop, Désirée van der Heijde, Paul Emery, Josef S Smolen, Helena Marzo-Ortega. Ann Rheum Dis 2012
179
12

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
431
12

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
Asta Baranauskaite, Helena Raffayová, N V Kungurov, Anna Kubanova, Algirdas Venalis, Laszlo Helmle, Shankar Srinivasan, Evgeny Nasonov, Nathan Vastesaeger. Ann Rheum Dis 2012
126
12

The Epidemiology of Psoriatic Arthritis.
Alexis Ogdie, Pamela Weiss. Rheum Dis Clin North Am 2015
213
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.